Congratulations to Bonnie Ky, MD, MSCE, FACC on winning the 2025 Distinguished Scientist Award (Translational Domain)! As a leader in #CardioOnc, her work is shaping the future of the field. #ACC25 #JACCCardioOnc @jaccjournals @pennthalheimer youtube.com/watch?v=I_meTO…

Proud of Baylor Scott & White Dallas-Fort Worth internal medicine resident, Dr. Hien Pham! She presented our case "Transmural Right Ventricular Involvment of Primary Cardiac ❤️ Lymphoma: A Case Study on Navigating Diagnosis & Treatment"

Happy to see our BUMC internal medicine residents presenting great work, learning the latest advances in cardiology, and having a good time at #ACC25 in Chicago this weekend!

Incredibly proud to be part of this family. American College of Cardiology #CardioOnc Section will turn 10 next year! I cannot think of a more resilient, inclusive & always-there-for-you community. Special kudos to Anita Deswal & Diego Sadler MD FACC on fearlessly leading the future!

10 year anniversary of #CardioOnc Section!?! Our new Community Building Work Group Chair Vijay Rao, MD, PhD has some work to do so that we properly celebrate at #ACC26! 🥳

The #JACCCardioOnc 3-part series provides evidence-based guidance and highlights gaps in CV care for patients before, during, & after cancer therapy. Explore the series ➡️ jacc.org/journal/cardio… #CardioOnc The Penn Thalheimer Center for Cardio-Oncology

#HeartDisease is the hallmark of Wild-Type transthyretin #amyloidosis (#ATTRwt), but it is commonly preceded by other conditions, such as carpal tunnel syndrome or spinal stenosis. Learn more about this devastating disease: arci.org/resource/disea…

Excellent study in JACC Journals focusing on I-124 evuzamitide in patients with "early" transthyretin amyloidosis ( having negative or quivocal bone scintigraphy (PYP)). Excellent performance of evuzamitide in this cohort. jacc.org/doi/10.1016/j.… #CardioTwitter

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

CART for AL NEXICART-2 trial. In phase 2 CR was the primary endpoint. 80% CRS but mostly grade 1. No ICANS or other MNT. Pretty amazing results with 100% CR or close. Also organ responses seen (expected) but more likely will come. #ASCO25

Excited to report to our GCOR colleagues about the Grant awarded for Cancer Innovation by FDOH for Florida! Cleveland Clinic Heart, Vascular & Thoracic Maroone Cancer at Cleveland Clinic Florida FLASCO American College of Cardiology International Cardio-Oncology Society Florida Chapter ACC Zeina Nahleh, MD, FACP European Society of Cardiology

Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions Latest review article with my colleagues Drs. Andrew Girard and Talal Asif pubmed.ncbi.nlm.nih.gov/40147532/

Excited to report this important collaboration which we hope helps us understand ICI-myocarditis better, published in #EHJ today! Along with the great DrJE-Salem! EHJ Editor-in-Chief Johann Bauersachs #CardioOnc UCSF Cardiology UCSF Helen Diller Family Comprehensive Cancer Ctr academic.oup.com/eurheartj/adva…

Reduced echo monitoring every 6 months is safe and feasible for low risk HER2+ BC patients, per #Anthony Yu et al. A key step toward evidence-based, risk-adapted monitoring. #CardioOnc #CTRCD JACC Journals Kazuhiro Sase dineshpmcc International Cardio-Oncology Society

Exercise is medicine. Physically active breast cancer survivors had 31% (95% CI: 25–37%) reduction in risk of breast cancer mortality relative to physically inactive pts. pmc.ncbi.nlm.nih.gov/articles/PMC12…

Another disappointment for #AL #amyloidosis #depleters: CARES didn’t meet its primary endpoint. What exactly was the prespecified subgroup that showed benefit? 🤔 Does this mean anything for #ATTR depleters? Time (and full data) will tell. reuters.com/business/healt…